|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In a case only analysis of G allele of rs738409 in PNPLA3 was associated with a decreased risk of zone 3 centered steatosis (OR = 0.46, 95% CI = 0.36-0.58; P = 5.15 x 10(-11)).
|
20648472 |
2010 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In CHB patients, the PNPLA3 I148M polymorphism influences susceptibility to steatosis and, in particular, when associated with severe overweight and alcohol intake, severe steatosis.
|
23564580 |
2013 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In children with NAFLD, the risk of severe steatosis is increased by SGA at birth, independent of and in addition to other powerful risk factors (insulin-resistance and I148M variant of the PNPLA3 gene).
|
28555633 |
2017 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In multivariate regression analysis, recipients who carried rs738409-GG had a 13.7-fold higher risk of graft steatosis than recipients who carried rs738409-CC (P = .022), independent of recipient age, weight gain after liver transplantation, or the underlying disease.
|
23872669 |
2013 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In patients with NAFLD, adiponutrin rs738409 C-->G genotype, encoding for I148M, is associated with the severity of steatosis and fibrosis and the presence of nonalcoholic steatohepatitis.
|
20373368 |
2010 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this large cohort of histologically proven NAFLD, we confirm the association of the rs738409 G allele with steatosis and describe its association with histological severity.
|
20684021 |
2010 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we show that only in subjects with hepatic steatosis, the OXFAs are associated with the CK-18 and that this association is modulated by the PNPLA3 rs738409 variant.
|
23815500 |
2014 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Meta-analysis showed that PNPLA3 rs738409 polymorphism exerted strong influence not only on fatty liver but also on the histological injury.
|
30762732 |
2019 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, we genotyped the same patients for the patatin-like phospholipase-containing domain 3 (PNPLA3) I148M polymorphism, which is implicated in the development of liver steatosis.
|
25250621 |
2014 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
No association between PNPLA3 rs738409/IL28B rs8099917 genotypes and hepatic steatosis or liver fibrosis was observed.
|
24349054 |
2013 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
One year after LT, steatosis was present in 50.0% of homozygous recipients with the rs738409-G allele.
|
28718984 |
2018 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our aim was to assess the impact of PNPLA3 rs738409 G-allele on steatosis in HCV patients.
|
24927606 |
2015 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.
|
25801076 |
2015 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
|
26765961 |
2016 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants were independent risk factors of hepatic steatosis and elevated ALT levels.
|
29314568 |
2018 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease.
|
30189691 |
2018 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409 minor allele c.444G represents a risk factor for liver steatosis and fibrosis progression also in chronic hepatitis C (HCV).
|
31527889 |
2019 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previous studies of the PNPLA3 I148M</span> sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis.
|
22978414 |
2012 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, a sequence variation within the gene encoding for patatin-like phospholipase containing 3 (PNPLA3, rs738409) was found to modulate steatosis, inflammation and fibrosis in NAFLD.
|
22884299 |
2013 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, the common variant p.I148M of the enzyme adiponutrin (PNPLA3) has emerged as a major genetic determinant of hepatic steatosis and nonalcoholic steatohepatitis as well as its pathobiological sequelae fibrosis, cirrhosis, and hepatocellular cancer.
|
24222094 |
2013 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, the PNPLA3 gene I148M (rs738409) variant was demonstrated to be strongly associated with hepatic steatosis in obese adults.
|
20546964 |
2010 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
|
26745555 |
2016 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Since DAG (FA18:1) has been implicated in hepatic insulin resistance, the unaltered proportion of DAG (FA18:1) in I148M PNPLA3 carriers with fatty liver may explain the normal insulin sensitivity in these subjects.
|
30227635 |
2018 |
|
Steatohepatitis
|
|
0.100 |
GeneticVariation
|
BEFREE |
SNP rs738409 in PNPLA3 was significantly associated with liver density (P=0.0075) and hepatic steatosis (P=0.0350), but not with blood glucose, HbA(1c), total cholesterol, triglycerides, high-density or low-density lipoprotein levels or liver function tests (P=0.15-0.96).
|
21665509 |
2011 |